Astragaloside IV regulates circ_0001615 and miR‐873‐5p/LASP1 axis to suppress colorectal cancer cell progression
Astragaloside IV (AS‐IV) has exhibited pivotal anti‐cancer efficacy in multiple types of cancer, including colorectal cancer (CRC). Meanwhile, circular RNA (circRNA) circ_0001615 has been reported to be involved in the malignant development of CRC. Herein, this study is expected to figure out the in...
Gespeichert in:
Veröffentlicht in: | Chemical biology & drug design 2024-01, Vol.103 (1), p.e14423-n/a |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 1 |
container_start_page | e14423 |
container_title | Chemical biology & drug design |
container_volume | 103 |
creator | Kong, Pengfei Tang, Xuemei Liu, Fang Tang, Xuegui |
description | Astragaloside IV (AS‐IV) has exhibited pivotal anti‐cancer efficacy in multiple types of cancer, including colorectal cancer (CRC). Meanwhile, circular RNA (circRNA) circ_0001615 has been reported to be involved in the malignant development of CRC. Herein, this study is expected to figure out the interaction between circ_0001615 and AS‐IV on CRC progression. The 50% inhibition concentration (IC50), proliferation, apoptosis, and migration were detected by Cell Counting Kit‐8 (CCK‐8), 5‐ethynyl‐2′‐deoxyuridine (EdU), flow cytometry, and wound healing assays. The expression of related proteins was examined by western blot. Circ_0001615, microRNA‐873‐5p (miR‐873‐5p), and LIM and SH3 protein 1 (LASP1) levels were detected by real‐time quantitative polymerase chain reaction (RT‐qPCR). The binding between miR‐873‐5p and circ_0001615, or LASP1, was predicted by Starbase, followed by verification by dual‐luciferase reporter and RNA immunoprecipitation (RIP) assays. The biological role of circ_0001615 and AS‐IV on CRC tumor growth was detected by the xenograft tumor model in vivo. According to the IC50 of AS‐IV in CRC cells, the 100 ng/mL AS‐IV treatment for 24 h was chosen for the following research: Our data confirmed that AS‐IV is a beneficial anti‐cancer agent in CRC cells. Furthermore, circ_0001615 and LASP1 expression were increased, and miR‐873‐5p was decreased in CRC patients and cell lines, whereas their expression exhibited an opposite trend in AS‐IV‐treated cells. Functionally, applying AS‐IV might act as a beneficial anti‐cancer effect by downregulating circ_0001615 in CRC cells in vitro. Mechanically, circ_0001615 serves as a sponge for miR‐873‐5p to affect LASP1 expression. In addition, AS‐IV inhibited CRC cell growth in vivo by modulating circ_0001615. Overall, AS‐IV could mitigate CRC development, at least in part, through the circ_0001615/miR‐873‐5p/LASP1 axis. These findings support a theoretical basis for an in‐depth study of the function of AS‐IV and the clinical treatment of CRC.
Applying astragaloside IV (AS‐IV) might repress the expression of circ_0001615 in colorectal cancer (CRC) cell lines. Furthermore, AS‐IV performed a beneficial anti‐cancer effect by regulating the circ_0001615/miR‐873‐5p/LASP1 network in the CRC. |
doi_str_mv | 10.1111/cbdd.14423 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2915987959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2915987959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3293-d473e6294956c07bebde63434e6e0239db97c5b7adadc5ef3cb36dc7a757cf1c3</originalsourceid><addsrcrecordid>eNp9kEtOwzAQhi0EoqWw4QDIS4SU1o7tOF6WlkelSiBeW8uxp1VQ2gQ7EXTHETgjJyGlpUtmMTPSfPPP6EfolJI-bWNgM-f6lPOY7aEulVxGJE7F_q6XsoOOQnglhHMRp4eow9KYESlZF9XDUHszN0UZcgd48oI9zJvC1BCwzb3VhBCaUIHN0uFF_vD9-ZVK1mZRDabDx3uKzUcecF3i0FSVh9CulUXpwdamwNYsLXhsoShw5cv5ep6Xy2N0MDNFgJNt7aHn66un0W00vbuZjIbTyLJYschxySCJFVcisURmkDlIGGccEiAxUy5T0opMGmecFTBjNmOJs9JIIe2MWtZD5xvd9vZbA6HWizysnzFLKJugY0WFSqUSqkUvNqj1ZQgeZrry-cL4laZEr13Wa5f1r8stfLbVbbIFuB36Z2sL0A3wnhew-kdKjy7H443oD7EEiNk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2915987959</pqid></control><display><type>article</type><title>Astragaloside IV regulates circ_0001615 and miR‐873‐5p/LASP1 axis to suppress colorectal cancer cell progression</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Kong, Pengfei ; Tang, Xuemei ; Liu, Fang ; Tang, Xuegui</creator><creatorcontrib>Kong, Pengfei ; Tang, Xuemei ; Liu, Fang ; Tang, Xuegui</creatorcontrib><description>Astragaloside IV (AS‐IV) has exhibited pivotal anti‐cancer efficacy in multiple types of cancer, including colorectal cancer (CRC). Meanwhile, circular RNA (circRNA) circ_0001615 has been reported to be involved in the malignant development of CRC. Herein, this study is expected to figure out the interaction between circ_0001615 and AS‐IV on CRC progression. The 50% inhibition concentration (IC50), proliferation, apoptosis, and migration were detected by Cell Counting Kit‐8 (CCK‐8), 5‐ethynyl‐2′‐deoxyuridine (EdU), flow cytometry, and wound healing assays. The expression of related proteins was examined by western blot. Circ_0001615, microRNA‐873‐5p (miR‐873‐5p), and LIM and SH3 protein 1 (LASP1) levels were detected by real‐time quantitative polymerase chain reaction (RT‐qPCR). The binding between miR‐873‐5p and circ_0001615, or LASP1, was predicted by Starbase, followed by verification by dual‐luciferase reporter and RNA immunoprecipitation (RIP) assays. The biological role of circ_0001615 and AS‐IV on CRC tumor growth was detected by the xenograft tumor model in vivo. According to the IC50 of AS‐IV in CRC cells, the 100 ng/mL AS‐IV treatment for 24 h was chosen for the following research: Our data confirmed that AS‐IV is a beneficial anti‐cancer agent in CRC cells. Furthermore, circ_0001615 and LASP1 expression were increased, and miR‐873‐5p was decreased in CRC patients and cell lines, whereas their expression exhibited an opposite trend in AS‐IV‐treated cells. Functionally, applying AS‐IV might act as a beneficial anti‐cancer effect by downregulating circ_0001615 in CRC cells in vitro. Mechanically, circ_0001615 serves as a sponge for miR‐873‐5p to affect LASP1 expression. In addition, AS‐IV inhibited CRC cell growth in vivo by modulating circ_0001615. Overall, AS‐IV could mitigate CRC development, at least in part, through the circ_0001615/miR‐873‐5p/LASP1 axis. These findings support a theoretical basis for an in‐depth study of the function of AS‐IV and the clinical treatment of CRC.
Applying astragaloside IV (AS‐IV) might repress the expression of circ_0001615 in colorectal cancer (CRC) cell lines. Furthermore, AS‐IV performed a beneficial anti‐cancer effect by regulating the circ_0001615/miR‐873‐5p/LASP1 network in the CRC.</description><identifier>ISSN: 1747-0277</identifier><identifier>EISSN: 1747-0285</identifier><identifier>DOI: 10.1111/cbdd.14423</identifier><identifier>PMID: 38230773</identifier><language>eng</language><publisher>England</publisher><subject>Adaptor Proteins, Signal Transducing ; Animals ; AS‐IV ; Cell Proliferation ; circ_0001615 ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Cytoskeletal Proteins ; Disease Models, Animal ; Humans ; LIM Domain Proteins ; MicroRNAs - genetics ; migration ; miR‐873‐5p ; proliferation ; Saponins - pharmacology ; Saponins - therapeutic use ; Triterpenes - pharmacology</subject><ispartof>Chemical biology & drug design, 2024-01, Vol.103 (1), p.e14423-n/a</ispartof><rights>2024 John Wiley & Sons A/S.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3293-d473e6294956c07bebde63434e6e0239db97c5b7adadc5ef3cb36dc7a757cf1c3</citedby><cites>FETCH-LOGICAL-c3293-d473e6294956c07bebde63434e6e0239db97c5b7adadc5ef3cb36dc7a757cf1c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcbdd.14423$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcbdd.14423$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38230773$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kong, Pengfei</creatorcontrib><creatorcontrib>Tang, Xuemei</creatorcontrib><creatorcontrib>Liu, Fang</creatorcontrib><creatorcontrib>Tang, Xuegui</creatorcontrib><title>Astragaloside IV regulates circ_0001615 and miR‐873‐5p/LASP1 axis to suppress colorectal cancer cell progression</title><title>Chemical biology & drug design</title><addtitle>Chem Biol Drug Des</addtitle><description>Astragaloside IV (AS‐IV) has exhibited pivotal anti‐cancer efficacy in multiple types of cancer, including colorectal cancer (CRC). Meanwhile, circular RNA (circRNA) circ_0001615 has been reported to be involved in the malignant development of CRC. Herein, this study is expected to figure out the interaction between circ_0001615 and AS‐IV on CRC progression. The 50% inhibition concentration (IC50), proliferation, apoptosis, and migration were detected by Cell Counting Kit‐8 (CCK‐8), 5‐ethynyl‐2′‐deoxyuridine (EdU), flow cytometry, and wound healing assays. The expression of related proteins was examined by western blot. Circ_0001615, microRNA‐873‐5p (miR‐873‐5p), and LIM and SH3 protein 1 (LASP1) levels were detected by real‐time quantitative polymerase chain reaction (RT‐qPCR). The binding between miR‐873‐5p and circ_0001615, or LASP1, was predicted by Starbase, followed by verification by dual‐luciferase reporter and RNA immunoprecipitation (RIP) assays. The biological role of circ_0001615 and AS‐IV on CRC tumor growth was detected by the xenograft tumor model in vivo. According to the IC50 of AS‐IV in CRC cells, the 100 ng/mL AS‐IV treatment for 24 h was chosen for the following research: Our data confirmed that AS‐IV is a beneficial anti‐cancer agent in CRC cells. Furthermore, circ_0001615 and LASP1 expression were increased, and miR‐873‐5p was decreased in CRC patients and cell lines, whereas their expression exhibited an opposite trend in AS‐IV‐treated cells. Functionally, applying AS‐IV might act as a beneficial anti‐cancer effect by downregulating circ_0001615 in CRC cells in vitro. Mechanically, circ_0001615 serves as a sponge for miR‐873‐5p to affect LASP1 expression. In addition, AS‐IV inhibited CRC cell growth in vivo by modulating circ_0001615. Overall, AS‐IV could mitigate CRC development, at least in part, through the circ_0001615/miR‐873‐5p/LASP1 axis. These findings support a theoretical basis for an in‐depth study of the function of AS‐IV and the clinical treatment of CRC.
Applying astragaloside IV (AS‐IV) might repress the expression of circ_0001615 in colorectal cancer (CRC) cell lines. Furthermore, AS‐IV performed a beneficial anti‐cancer effect by regulating the circ_0001615/miR‐873‐5p/LASP1 network in the CRC.</description><subject>Adaptor Proteins, Signal Transducing</subject><subject>Animals</subject><subject>AS‐IV</subject><subject>Cell Proliferation</subject><subject>circ_0001615</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Cytoskeletal Proteins</subject><subject>Disease Models, Animal</subject><subject>Humans</subject><subject>LIM Domain Proteins</subject><subject>MicroRNAs - genetics</subject><subject>migration</subject><subject>miR‐873‐5p</subject><subject>proliferation</subject><subject>Saponins - pharmacology</subject><subject>Saponins - therapeutic use</subject><subject>Triterpenes - pharmacology</subject><issn>1747-0277</issn><issn>1747-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtOwzAQhi0EoqWw4QDIS4SU1o7tOF6WlkelSiBeW8uxp1VQ2gQ7EXTHETgjJyGlpUtmMTPSfPPP6EfolJI-bWNgM-f6lPOY7aEulVxGJE7F_q6XsoOOQnglhHMRp4eow9KYESlZF9XDUHszN0UZcgd48oI9zJvC1BCwzb3VhBCaUIHN0uFF_vD9-ZVK1mZRDabDx3uKzUcecF3i0FSVh9CulUXpwdamwNYsLXhsoShw5cv5ep6Xy2N0MDNFgJNt7aHn66un0W00vbuZjIbTyLJYschxySCJFVcisURmkDlIGGccEiAxUy5T0opMGmecFTBjNmOJs9JIIe2MWtZD5xvd9vZbA6HWizysnzFLKJugY0WFSqUSqkUvNqj1ZQgeZrry-cL4laZEr13Wa5f1r8stfLbVbbIFuB36Z2sL0A3wnhew-kdKjy7H443oD7EEiNk</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Kong, Pengfei</creator><creator>Tang, Xuemei</creator><creator>Liu, Fang</creator><creator>Tang, Xuegui</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202401</creationdate><title>Astragaloside IV regulates circ_0001615 and miR‐873‐5p/LASP1 axis to suppress colorectal cancer cell progression</title><author>Kong, Pengfei ; Tang, Xuemei ; Liu, Fang ; Tang, Xuegui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3293-d473e6294956c07bebde63434e6e0239db97c5b7adadc5ef3cb36dc7a757cf1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adaptor Proteins, Signal Transducing</topic><topic>Animals</topic><topic>AS‐IV</topic><topic>Cell Proliferation</topic><topic>circ_0001615</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Cytoskeletal Proteins</topic><topic>Disease Models, Animal</topic><topic>Humans</topic><topic>LIM Domain Proteins</topic><topic>MicroRNAs - genetics</topic><topic>migration</topic><topic>miR‐873‐5p</topic><topic>proliferation</topic><topic>Saponins - pharmacology</topic><topic>Saponins - therapeutic use</topic><topic>Triterpenes - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kong, Pengfei</creatorcontrib><creatorcontrib>Tang, Xuemei</creatorcontrib><creatorcontrib>Liu, Fang</creatorcontrib><creatorcontrib>Tang, Xuegui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemical biology & drug design</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kong, Pengfei</au><au>Tang, Xuemei</au><au>Liu, Fang</au><au>Tang, Xuegui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Astragaloside IV regulates circ_0001615 and miR‐873‐5p/LASP1 axis to suppress colorectal cancer cell progression</atitle><jtitle>Chemical biology & drug design</jtitle><addtitle>Chem Biol Drug Des</addtitle><date>2024-01</date><risdate>2024</risdate><volume>103</volume><issue>1</issue><spage>e14423</spage><epage>n/a</epage><pages>e14423-n/a</pages><issn>1747-0277</issn><eissn>1747-0285</eissn><abstract>Astragaloside IV (AS‐IV) has exhibited pivotal anti‐cancer efficacy in multiple types of cancer, including colorectal cancer (CRC). Meanwhile, circular RNA (circRNA) circ_0001615 has been reported to be involved in the malignant development of CRC. Herein, this study is expected to figure out the interaction between circ_0001615 and AS‐IV on CRC progression. The 50% inhibition concentration (IC50), proliferation, apoptosis, and migration were detected by Cell Counting Kit‐8 (CCK‐8), 5‐ethynyl‐2′‐deoxyuridine (EdU), flow cytometry, and wound healing assays. The expression of related proteins was examined by western blot. Circ_0001615, microRNA‐873‐5p (miR‐873‐5p), and LIM and SH3 protein 1 (LASP1) levels were detected by real‐time quantitative polymerase chain reaction (RT‐qPCR). The binding between miR‐873‐5p and circ_0001615, or LASP1, was predicted by Starbase, followed by verification by dual‐luciferase reporter and RNA immunoprecipitation (RIP) assays. The biological role of circ_0001615 and AS‐IV on CRC tumor growth was detected by the xenograft tumor model in vivo. According to the IC50 of AS‐IV in CRC cells, the 100 ng/mL AS‐IV treatment for 24 h was chosen for the following research: Our data confirmed that AS‐IV is a beneficial anti‐cancer agent in CRC cells. Furthermore, circ_0001615 and LASP1 expression were increased, and miR‐873‐5p was decreased in CRC patients and cell lines, whereas their expression exhibited an opposite trend in AS‐IV‐treated cells. Functionally, applying AS‐IV might act as a beneficial anti‐cancer effect by downregulating circ_0001615 in CRC cells in vitro. Mechanically, circ_0001615 serves as a sponge for miR‐873‐5p to affect LASP1 expression. In addition, AS‐IV inhibited CRC cell growth in vivo by modulating circ_0001615. Overall, AS‐IV could mitigate CRC development, at least in part, through the circ_0001615/miR‐873‐5p/LASP1 axis. These findings support a theoretical basis for an in‐depth study of the function of AS‐IV and the clinical treatment of CRC.
Applying astragaloside IV (AS‐IV) might repress the expression of circ_0001615 in colorectal cancer (CRC) cell lines. Furthermore, AS‐IV performed a beneficial anti‐cancer effect by regulating the circ_0001615/miR‐873‐5p/LASP1 network in the CRC.</abstract><cop>England</cop><pmid>38230773</pmid><doi>10.1111/cbdd.14423</doi><tpages>16</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1747-0277 |
ispartof | Chemical biology & drug design, 2024-01, Vol.103 (1), p.e14423-n/a |
issn | 1747-0277 1747-0285 |
language | eng |
recordid | cdi_proquest_miscellaneous_2915987959 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Adaptor Proteins, Signal Transducing Animals AS‐IV Cell Proliferation circ_0001615 Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Cytoskeletal Proteins Disease Models, Animal Humans LIM Domain Proteins MicroRNAs - genetics migration miR‐873‐5p proliferation Saponins - pharmacology Saponins - therapeutic use Triterpenes - pharmacology |
title | Astragaloside IV regulates circ_0001615 and miR‐873‐5p/LASP1 axis to suppress colorectal cancer cell progression |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A16%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Astragaloside%20IV%20regulates%20circ_0001615%20and%20miR%E2%80%90873%E2%80%905p/LASP1%20axis%20to%20suppress%20colorectal%20cancer%20cell%20progression&rft.jtitle=Chemical%20biology%20&%20drug%20design&rft.au=Kong,%20Pengfei&rft.date=2024-01&rft.volume=103&rft.issue=1&rft.spage=e14423&rft.epage=n/a&rft.pages=e14423-n/a&rft.issn=1747-0277&rft.eissn=1747-0285&rft_id=info:doi/10.1111/cbdd.14423&rft_dat=%3Cproquest_cross%3E2915987959%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2915987959&rft_id=info:pmid/38230773&rfr_iscdi=true |